We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+13.94%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$284M
AUM Growth
+$26.8M
Cap. Flow
+$26.8M
Cap. Flow %
9.46%
Top 10 Hldgs %
45.99%
Holding
71
New
15
Increased
14
Reduced
11
Closed
6

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.32M
2
SHPG
Shire pic
SHPG
+$4.62M
3
EXEL icon
Exelixis
EXEL
+$4.15M
4
TSRO
TESARO, Inc.
TSRO
+$4.15M
5
STML
Stemline Therapeutics, Inc.
STML
+$4.15M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$5.75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$4.98M
3
CALA
Calithera Biosciences, Inc
CALA
+$2.95M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$2.4M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 99.5%
2 Miscellaneous 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$2.05B
$1.14M 0.4%
20,000
– –
HZNP
52
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.01M 0.36%
69,000
– –
FSTX
53
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$956K 0.34%
+18,250
New +$1.09M
ONC
54
BeOne Medicines Ltd
ONC
$42.1B
$928K 0.33%
+9,500
New +$870K
AERI
55
DELISTED
Aerie Pharmaceuticals
AERI
$883K 0.31%
14,779
– –
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
$843K 0.3%
58,600
– –
SUPN icon
57
Supernus Pharmaceuticals
SUPN
$2.57B
$834K 0.29%
20,953
– –
GTHX
58
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$773K 0.27%
39,000
– –
OMER icon
59
Omeros
OMER
$1.39B
$660K 0.23%
34,000
-27,000
-44% -$506K
ONCE
60
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$617K 0.22%
12,000
– –
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
$597K 0.21%
18,799
– –
PRTA icon
62
Prothena Corp
PRTA
$467M
$562K 0.2%
+15,000
New +$764K
XNCR icon
63
Xencor
XNCR
$2.15B
$395K 0.14%
18,000
– –
VKTX icon
64
Viking Therapeutics
VKTX
$3.95B
$284K 0.1%
+70,000
New +$203K
ASMB icon
65
Assembly Biosciences
ASMB
$709M
– –
-425
Closed -$178K
CORT icon
66
Corcept Therapeutics
CORT
$12.6B
– –
-83,000
Closed -$1.6M
IRWD icon
67
Ironwood Pharmaceuticals
IRWD
$701M
– –
-70,446
Closed -$930K
VCYT icon
68
Veracyte
VCYT
$3.64B
– –
-170,000
Closed -$1.49M
CALA
69
DELISTED
Calithera Biosciences, Inc
CALA
– –
-9,400
Closed -$2.95M
XLRN
70
DELISTED
Acceleron Pharma
XLRN
– –
-153,633
Closed -$5.75M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2017 Portfolio in Review

As of Q4 2017, International Biotechnology Trust held 71 positions worth $284M, up 10% from $257M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

International Biotechnology Trust deployed $26.8M of net new capital in Q4 2017, opening 15 new positions and adding to 14 existing holdings. Its largest new stake was Nektar Therapeutics: 14,067 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $4.98M trimmed.

  • International Biotechnology Trust's largest Q4 2017 buy was Nektar Therapeutics: 14,067 shares worth $12.6M.
  • International Biotechnology Trust added most to Exelixis in Q4 2017, an estimated $4.15M increase.
  • International Biotechnology Trust's biggest Q4 2017 reduction was Sarepta Therapeutics, cutting an estimated $4.98M.
  • International Biotechnology Trust fully exited Acceleron Pharma in Q4 2017, selling an estimated $5.75M.
  • International Biotechnology Trust's ten largest holdings make up 46% of its $284M portfolio in Q4 2017.
  • International Biotechnology Trust opened 15 new positions and closed 6 in Q4 2017.
  • International Biotechnology Trust's portfolio value rose 10% quarter-over-quarter to $284M.

Based on International Biotechnology Trust's 13F filing for Q4 2017, filed 2 Mar 2018.